Scientific Programme, ePosters & Abstracts

ESPE Abstracts (2021) 94 P2-268

ESPE2021 ePoster Category 2 Growth hormone and IGFs (31 abstracts)

Growth response to growth hormone therapy in short children in relation to their distance from mid-parental heights (MPHt).

Sohair Elsiddig , Ashraf Soliman , Nada Alaaraj , Ahmed Khalil & Hannah Ahmed


Hamad General Hospital, Doha, Qatar


In normal children, mid parental height (MPH) is a useful tool in assessing children’s growth and in the prediction of their final adult height. However, this may not be true for short children, especially those with height SD (HtSDS) > - 1SDS compared to their mid-parental height SDS (MPHtSDS). The difference may indicate underlying pathology.

Aim: To assess growth response (change in HtSDS) to GH therapy in short prepubertal children in relation to their MPHtSDS.

Methods: This retrospective study reviewed 42 prepubertal short children with HtSDS <-2. Children classified based on distance from MPHtSDS in two groups. Group1 included children whose HtSDS were 1SDS or more below their MPHSDS (n = 25). Group 2 whose HtSDS less than 1SDS from MPHSDS (n = 17). Their BMISDS, IGF1SDS, bone age and growth velocity (GV), and difference from MPHSDS were measured before and after one year. Sixteen children in Group 1 and 11 children in group 2 were treated with growth hormone therapy (0.03- 0.5 mg/kg/d) subcutaneously to keep their IGF1 SD in the normal range (0 to 2 SD).

Result: Children in group 1 had HtSDS - MPHSDS = -1.72±0.52 while in group 2 the difference was -0.33±0.75. (P <0.01). Children in Group 1 were significantly shorter compared to group 2 (HtSDS (-2.35±0.57) vs. (-1.89±0.61) respectively P = 0.02). There was no statistical difference in BMISDS, IGF1SDS, or bone age at presentation. After One year of GH therapy the HtSDS of children in the group an increased to -2.01±0.59, (P = 0.005), and their difference from MPHSDS improved by (0.67±0.85) P < 0.0000. In group 2 the HtSDS increased to -1.66±0.68, (P < 0.01) and their difference from MPHSDS improved by (0.30±0.32) (P = 0.01)

Age HtSDS1BMISDS1HtSDS1-MPHSDSHtSDS2BMISDS2HtSDS2-MPHSDSDelta HtSDSDelta HtSDS-MPHSDS
Group 110.55-2.35*-0.84-1.72*-2.01-0.57-1.38*0.330.67
2.850.570.940.520.591.110.520.520.85
#P0.0050.90.000
Group 29.48-1.89-0.16-0.33-1.66-0.09-0.040.200.30
3.870.611.170.700.681.130.910.300.32
#P0.010.20.01
*P < 0.05 between the two groups#<0.05 in the same group

Conclusion: This short prepubertal and peripubertal GH therapy had significantly increased their HTSDS and improved the difference between their height and their genetic background (MPHtSDS). Those who had a higher difference compared to MPHTSDS at the beginning had significantly faster correction towards their genetic potential (significant catch up towards the genetic background).

Article tools